
OTIC
Healthcare · Biotechnology · $582,482 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 8, 2023 | Time not confirmed | -0.03 | 0.00 | +100.0% |
| Mar 2, 2023 | Time not confirmed | -0.16 | 0.00 | +100.0% |
| Nov 10, 2022 | After the close | -0.19 | -0.18 | +5.3% |
| Jul 25, 2022 | After the close | -0.20 | -0.19 | +5.0% |
| May 9, 2022 | After the close | -0.20 | -0.20 | 0.0% |
| Feb 28, 2022 | After the close | -0.18 | -0.20 | -11.1% |
| Nov 10, 2021 | After the close | -0.18 | -0.19 | -5.6% |
| Aug 4, 2021 | After the close | -0.18 | -0.19 | -5.6% |
| May 11, 2021 | After the close | -0.21 | -0.23 | -9.5% |
| Feb 11, 2021 | After the close | -0.21 | -0.20 | +4.8% |
| Nov 4, 2020 | After the close | -0.23 | -0.22 | +4.3% |
| Aug 4, 2020 | After the close | -0.37 | -0.37 | 0.0% |
| May 7, 2020 | Before the open | -0.36 | -0.38 |
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of…
| -5.6% |
| Feb 27, 2020 | After the close | -0.44 | -0.36 | +18.2% |
| Nov 5, 2019 | After the close | -0.45 | -0.33 | +26.7% |
| Aug 1, 2019 | After the close | -0.48 | -0.38 | +20.8% |
| May 6, 2019 | After the close | -0.43 | -0.39 | +9.3% |
| Mar 4, 2019 | After the close | -0.48 | -0.42 | +12.5% |
| Nov 5, 2018 | After the close | -0.47 | -0.41 | +12.8% |
| Aug 8, 2018 | After the close | -0.38 | -0.44 | -15.8% |
| May 9, 2018 | After the close | -0.35 | -0.37 | -5.7% |
| Mar 8, 2018 | After the close | -0.60 | -0.62 | -3.3% |